Prostate cancer is the most common solid tumor in American men and is the second most common cause of cancer deaths. Although surgery and radiation therapy are effective for the treatment of organ-confined cancer, there is no effective treatment that is currently available for patients who have metastatic disease. Antiandrogen therapy is only palliative, and chemotherapy has largely been ineffective. However, recent advances in the understanding of the molecular biology of prostate cancer have lead to the development of new treatment strategies for metastatic cancer, including gene-based therapies, immunotherapies, and antiangiogenesis-based therapy. In association with the Jonsson Comprehensive Cancer Center and the University of California, Los Angeles Department of Urology, the Jennifer Jones Simon Foundation assembled 30 of the world's experts in prostate cancer research to review the most recent advances in the study of prostate cancer, with the hope that the resulting discussions would facilitate the rapid translation of new discoveries from the laboratory bench to the clinic.

1

This work was supported by Janssen Pharmaceuticals and Chiron Therapeutics. This report is from a symposium that was sponsored by the Jennifer Jones Simon Foundation and was held on January 30–31, 1998, on the campus of the UCLA School of Medicine in Los Angeles, CA. The participants included: Dr. David Baltimore from the California Institute of Technology; Dr. Neil H. Bander from the New York Hospital/Cornell Medical Center; Dr. Arie Belldegrun from the UCLA School of Medicine; Dr. Karen Bernstein from BioCentury; Dr. Martin A. Cheever from Corixa Corporation (Seattle, WA); Dr. Carlo Croce from the Kimmel Cancer Institute; Jean B. deKernion from the UCLA School of Medicine; Dr. Robert A. Figlin from the UCLA School of Medicine; Dr. Olivera Finn from the University of Pittsburgh Cancer Institute; Dr. Norman Greenberg from the Baylor College of Medicine; Dr. Harvey Herschman from the UCLA School of Medicine; Dr. Guido W. Jenster from the M. D. Anderson Cancer Center; Dr. Phillip W. Kantoff from the Dana Farber Cancer Institute; Dr. Roger Kirby from St. George's Hospital, London, United Kingdom; Dr. Paul Lange from the University of Washington Medical Center; Dr. Judd W. Moul from the Uniformed Services University of the Health Sciences; Dr. Leena Peltonen from the University of Helsinki; Dr. Michael Phelps from the UCLA School of Medicine; Dr. David Reese from the UCLA School of Medicine; Dr. Gert J. C. Riethmueller from the University of Munich; Dr. Neal Rosen from the Memorial Sloan-Kettering Cancer Center; Dr. Charles Sawyers from the UCLA School of Medicine; Dr. Peter Scardino from the Baylor College of Medicine; Dr. Jack A. Schalken from the University Hospital Nijmegen (Nijmegen, the Netherlands); Dr. Jan Schnitzer from the Beth Isreal Deaconess Medical Center; Dr. Hans Schrieber from the Beth Israel Deaconess Medical Center; Dr. Donald J. Tindall from the Mayo Clinic; Dr. Inder Verma from the Salk Institute (La Jolla, CA); Dr. Tapio Visakorpi from the Finland Institute of Medical Technology (Tampere, Finland); and Dr. Owen Witte from the Howard Hughes Medical Institute, UCLA.

This content is only available via PDF.
©1998 American Association for Cancer Research.
1998
American Association for Cancer Research, Inc.